Sleep is generally considered to be a protected period, when the cardiovascular system benefits from the restorative influences of the sleeping brain. However, the dynamics of cardiovascular control during sleep can tax the capacity of the diseased coronary circulation and myocardium with surges in sleep-state–related autonomic activity and disruptions in airway function and central nervous system regulation. In this regard, sleep may constitute an autonomic stress test for the heart.

The scope of sleep-related risk for atrial and ventricular arrhythmias is substantial. The major subgroups susceptible to adverse influences of surges in autonomic activity during sleep are those with ischemic heart disease, heart failure, and channelopathies (Table). It is significant that 20% of myocardial infarctions and 15% of sudden deaths occur at night in the United States. Most atrial arrhythmias in patients younger than 61 years of age have nocturnal onset. The young are not immune to risk, as sudden infant death syndrome (SIDS) claims 2500 lives in the United States annually. Cardiovascular risk is compounded by comorbid factors, most notably apnea, which affects an estimated 4% to 9% of the general population and is considerably more prevalent among obese individuals. The more common form is obstructive sleep apnea (OSA), with partial or complete collapse of the pharynx. Half of heart failure patients experience either OSA or central sleep apnea (CSA) with central nervous system–mediated periodic breathing, commonly referred to as Cheyne-Stokes respiration. Such cardiorespiratory disturbances profoundly alter autonomic nervous system activity and increase risk of arrhythmia, hypertension, and myocardial infarction.

It is surprising, as recently underscored by Malhotra and Loscalzo, that the significance of cardiovascular risk during sleep may not be duly recognized within the cardiology community. The reasons are unclear but in part relate to the complex nature of cardiorespiratory interactions during sleep and to lack of monitoring technology suitable for use during the normal flow of clinical evaluation.

The goals of the present review are to discuss briefly the main scientific underpinnings of the link between sleep and cardiac arrhythmias, to review clinical evidence and current understanding of the impact of sleep on atrial and ventricular arrhythmogenesis, and to consider recent developments that can improve opportunities for evaluation of risk within existing diagnostic platforms for 24-hour ECG monitoring, particularly streamlined technology for concurrent monitoring of sleep state, ECG, oxygen desaturation, and respiration.

**Sleep-State Control of Cardiovascular Function**

Preserving circulatory homeostasis during sleep requires coordination of control over 2 complex systems: the respiratory, sustaining essential oxygen exchange, and the cardiovascular, providing blood transport. The dynamics of respiration and heart rhythm vary greatly between sleep states. The difficult balancing act of regulating 2 motor systems, 1 that supplies somatic musculature (ie, diaphragmatic, intercostal, abdominal, and upper airway musculature) and 1 involving regulation of autonomic pathways to the heart and vasculature, is a remarkable task during sleep. The challenge is compounded among individuals with diseased respiratory or cardiovascular systems, such as those with apnea and/or heart failure, and in infants, whose control systems are underdeveloped. Mechanisms underlying sleep-state control of cardiovascular function have been discussed in detail.

Nonrapid eye movement (nonREM) sleep, the initial stage, occupies approximately 80% of sleep time. It is a period of lessened metabolic demands, with relative autonomic stability, when vagus nerve activity is dominant, baroreceptor gain is high, and sympathetic nerve activity is stable, with input to the cardiovascular system reduced by more than half from wakefulness to stage 4 of nonREM sleep. A near sinusoidal modulation of heart rate variation results from coupling of respiratory activity and cardiorespiratory centers in the brain to establish normal respiratory sinus arrhythmia, which is generally indicative of cardiac health. Heart rates accelerate briefly during inspiration to accommodate increased venous return and to provide increased cardiac output followed by progressive slowing in rate during expiration. The absence of this intrinsic variability in heart rate, which can be monitored by heart rate variability analysis, has been associated with cardiac pathology and advancing age, with the common denominator of loss of normal vagus nerve function.

Increased vagus nerve activity provokes bradycardias, and reduced sympathetic vasomotor tone results in hypotension. During transitions from nonREM to rapid eye movement (REM) sleep, bursts of vagus nerve activity may result in pauses in heart rhythm and frank asystole. Thus, in general,
the autonomic stability of nonREM sleep, with relative hypotension, bradycardia, and reduced cardiac output and systemic vascular resistance, provides a salutary neurohumoral background during which the heart has an opportunity for metabolic restoration. REM sleep is initiated at 90-minute intervals, when the brain’s increased excitability can disrupt cardiorespiratory homeostasis. Major surges in cardiac sympathetic nerve activity are concentrated in short, irregular periods, reach levels higher than during wakefulness, and trigger intermittent striking surges in blood pressure and heart rate, with marked episodes of tachycardia and bradycardia. Cardiac efferent vagus nerve tone is generally suppressed, and baroreceptor gain is reduced. Breathing patterns are also highly irregular and can provoke oxygen desaturation, particularly in patients with pulmonary or cardiac disease.

Ventricular Arrhythmias
Ventricular arrhythmias are generally suppressed during sleep in parallel with the nocturnal trough in incidence of myocardial infarction, sudden cardiac death, implantable cardioverter-defibrillator discharge, and myocardial ischemic events. However, sleep is not an entirely protected period, as 15% of sudden cardiac deaths occur at night or 48,750 cases annually in the United States alone. Moreover, the nighttime distribution of these events is nonuniform (Figure 1), suggesting physiological triggering.

REM sleep–related surges in sympathetic nerve activity have been implicated in nocturnal ventricular arrhythmias and myocardial ischemia in patients with cardiovascular disease. The specific mechanisms of REM-induced cardiac events include direct effects on electrophysiological stability or indirect effects of heart rate and arterial blood pressure accelerations, which may promote intraarterial platelet aggregation or disrupt plaques to release proarrhythmic constituents. As metabolic demand outstrips supply, neural activity may also trigger myocardial ischemia and/or arrhythmias, particularly in patients with endothelial dysfunction, coronary obstructive disease, or vasospasm.
The nocturnal decline in sympathetic nerve activity typical of healthy individuals is altered in patients with coronary artery disease, myocardial infarction, and diabetes, suggesting a decrease in vagus nerve activity during sleep and unopposed cardiac sympathetic nerve activity in these patients, a state conducive to ventricular tachycardia and fibrillation. Changes in cardiac substrate and mechanical function caused by disease, infarction, or ageing can also amplify nocturnal cardiac electric instability. After major surgery, the simultaneous occurrence of hypoxemia and tachycardia during sleep may promote myocardial ischemia. Frequent or complex arrhythmias typify hypertensive patients who do not exhibit the nocturnal trough in blood pressure. REM-related nocturnal arrhythmogenesis may have a significant affective component, as REM sleep dreams may be vivid, bizarre, and emotionally intense, and generate anger and fear, emotions that have been linked in wakefulness to onset of myocardial infarction and sudden death.

In some cases, arrhythmia frequency may be enhanced during nonREM sleep, when latent slow rhythms are exposed by the generalized reduction in heart rate after withdrawal of overdrive suppression. Also, relative hypotension during sleep may exacerbate impaired coronary perfusion as a result of lowered blood pressure gradients in stenosed vessels. A marked nocturnal peak in sudden death has been observed in patients with cardiac disease who experience obstructive or central sleep apnea. This respiratory dysfunction affects 15 million Americans. Apneic episodes and oxygen desaturation are highly conducive to nocturnal ischemia, bradyarrhythmias and tachyarrhythmias in patients with coronary artery disease, with heart failure, or in the subacute phase after myocardial infarction (Figure 2). Apneas are closely associated in time with subsequent onset of nonsustained ventricular tachycardia (Figure 3). The postulated mechanism is the accompanying surge in arterial blood pressure and sympathetic nerve activity, which attain levels observed during waking and achieve 249% to 299% above baseline (Figure 4). Episodic or chronic oxygen desaturation may contribute to the association of apnea with arrhythmias because it constitutes an independent marker of ventricular arrhythmia risk. Importantly, patients with sleep apnea exhibit elevated sympathetic nerve activity and blood pressure even during wakefulness.

Sleep apnea also potentiates the risk for cardiovascular events including nocturnal myocardial infarction and death from fatal myocardial infarction in patients with cardiovascular disease. Increased incidence of myocardial infarction in patients with sleep apnea may contribute to ventricular arrhythmias and sudden death due to ventricular remodeling and myocardial scar. Resistance-vessel endothelium-dependent vasodilation is impaired in patients with sleep apnea, a potential factor in the development of hypertension and heart failure.
Antiarrhythmic therapy should address the electrically unstable myocardial substrate, as for daytime arrhythmias. Nocturnal \( \beta \)-adrenergic receptor blockade may prove helpful in cases with marked surges in sympathetic nerve activity, with careful attention to avoiding medications that disrupt sleep. Antihypertensive pharmacological therapy may exacerbate the hypotensive effect of nonREM sleep and introduce the risk of transient ischemia in patients with stenotic lesions in the heart or brain, with potential for myocardial infarction.\(^{11}\) Thus, caution with respect to dosing is necessary. In patients with obstructive sleep apnea, weight control is therapeutic when warranted, and continuous positive airway pressure (CPAP) lessens arrhythmia risk\(^{33,34,38–40}\) and hypertension.\(^{41}\)

![Figure 4](image-url)Recording of sympathetic nerve activity (SNA), respiration (RESP), and intra-arterial blood pressure (BP) in the same subject when awake, with obstructive sleep apnea during REM sleep, and with elimination of obstructive apnea by continuous positive airway pressure (CPAP) therapy during REM sleep.\(^{31}\) SNA was very high during wakefulness but increased even further secondary to obstructive apnea during REM. BP increased from 130/65 mm Hg when awake to 256/110 mm Hg at the end of apnea. Elimination of apneas by CPAP resulted in decreased nerve activity and prevented BP surges during REM sleep. Reprinted with permission from The American Society for Clinical Investigation.

**Post–Myocardial Infarction**

During the first weeks after myocardial infarction, sleep is significantly disturbed,\(^{17}\) and nocturnal oxygen desaturation, especially in patients with impaired left ventricular function, may be generalized or episodic and directly provoke tachycardia, ventricular premature beats, and ST-segment changes.\(^{25,27,42}\) Both the duration and number of nighttime ischemic events are increased,\(^{16}\) consonant with elevated cardiac sympathetic nerve activity or decreased parasympathetic nerve activity,\(^{10}\) particularly in patients with residual myocardial ischemia. Nocturnal levels of norepinephrine are increased, and nocturnal secretion of melatonin, an endogenous hormone that suppresses sympathetic nerve activity, is impaired. These symptoms lessen across the first 6 months; after that period, ventricular tachycardia during sleep is relatively rare.

**Heart Failure**

An estimated 20% of sudden deaths in patients with heart failure occur at night.\(^{43}\) At least half of patients with congestive heart failure experience disturbed nighttime breathing in the form of either obstructive or central sleep apnea. Although the prevalence of OSA is comparable between men (38%) and women (31%) with heart failure, CSA is uncommon in women.\(^{21,22}\) The specific pathophysiological mechanisms that exacerbate heart failure differ between the apnea types. Whereas OSA is characterized by mechanical influences caused by airway obstruction, CSA has a critical central nervous system component and distinct periodic Cheyne-Stokes breathing.

These sleep-related nocturnal breathing disorders set in motion a cascade of arrhythmogenic factors\(^{44}\) and underlie an overall increase in mortality rates.\(^{5,45–47}\) Among the most important effects of central and obstructive sleep apnea are nocturnal oxygen desaturations,\(^{44}\) elevated sympathetic tone,\(^{21,22}\) ventricular stretch, remodeling of cardiac chambers, and left ventricular diastolic dysfunction. In patients with systolic heart failure, central sleep apnea, severe right ventricular systolic dysfunction, and low diastolic blood pressure are associated with increased mortality risks (Figure 5).\(^{48}\) The apnea-hypopnea index is a powerful independent predictor of poor prognoses in clinically stable congestive heart failure patients.\(^{49}\) Clearly, the underlying pathophysiological mechanisms of the 2 forms of apnea are complex and are critical in diagnosis and selection of therapy, as discussed in recent reviews.\(^{5,21,22,26}\)

**Detection of Arrhythmia Vulnerability in Heart Failure Patients**

Although arrhythmias are generally present in heart failure, specific methods for quantifying risk for malignant ventricular arrhythmias have been lacking. Recently, ambulatory
ECG-based T-wave alternans, a beat-to-beat fluctuation in the amplitude and shape of the T wave, has been shown to be a marker of risk for life-threatening tachyarrhythmias in patients with left ventricular dysfunction. A recent sizeable prospective study of patients with left ventricular dysfunction demonstrated that ambulatory ECG-based T-wave alternans can identify patients’ 1-year risk for cardiovascular mortality (primary end point) and sudden cardiac death (secondary end point) with odds ratios of 17.1 and 22.6, respectively (Figure 6). An example of elevated T-wave alternans during nighttime ambulatory ECG recording from a hospitalized heart failure patient is provided (Figure 7).

Preliminary evidence of a correlation between the severity of sleep apnea, indicated by oxygen desaturation and apnea-hypopnea index, with T-wave alternans magnitude in patients with congestive heart failure has also been reported.

Contemporary Therapeutic Approaches
Apnea treatment with CPAP, supplemental oxygen, medications, or mechanical breathing-assist devices can improve exercise tolerance and lessen heart failure symptoms. Its efficacy as an adjunct for arrhythmia prevention or management in patients with obstructive or central sleep apnea is controversial. Cardiac resynchronization therapy may reduce central sleep apnea and improve sleep quality because it promotes reverse remodeling with antiarrhythmic potential. Atrial overdrive pacing does not reduce the number of episodes of central or obstructive sleep apnea. The role of ICD implantation for primary prevention of sudden death in patients with left ventricular dysfunction requires further investigation.

Nocturnal Asystole and QT Interval Changes
Benign asystoles are not uncommon during sleep in normal individuals who are young or physically fit, such as athletes and heavy laborers. Sinus pauses <2 seconds, prolonged atrioventricular (AV) conduction, Wenckebach AV block, and bradycardia are attributed to effects of increased parasympathetic activity on AV node conduction. Periods of sinus arrest of up to 9 seconds during REM sleep in young adults with apparently normal cardiac function have been reported and attributed to exaggerated, if not abnormally elevated, vagal tone. However, in patients with coronary atherosclerosis and damaged endothelium, the acetylcholine released by surges in vagus nerve activity could provoke vasoconstriction as the result of impaired release of endothelium-derived relaxing factor.

Nocturnal prolonged cycle lengths and asystolic events can facilitate the occurrence of early afterdepolarizations and set the stage for ventricular arrhythmias including torsades de pointes in patients who are predisposed to this arrhythmia. Sleep-related cycle-length prolongation may also be a risk factor in patients treated with agents with class III antiarrhythmic effects or with diuretics, which lower potassium. Thus, determining the presence or absence of nocturnal heart rate pauses is important in treating individuals for whom class

Figure 6. Freedom from cardiac mortality based on modified moving average analysis of T-wave alternans (TD-TWA) from 24-hour ambulatory ECGs in ischemic (A) and nonischemic (B) study subgroups. Reprinted with permission from Heart Rhythm Society.

Figure 7. Representative rhythm strip (left) and QRS-aligned superimposed modified moving average waveforms (right) for the maximum T-wave alternans (≥65 μV) in lead V3 from a patient with heart failure who was enrolled in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Note the lack of separation between the superimposed beats in the isoelectric PQRS complex, indicating the low level of noise. The visible separation between the successive alternating beats is concentrated within the JT segment, as observed experimentally and in other clinical studies. Reprinted from permission from John Wiley & Sons.
III antiarrhythmic drugs (potassium channel blockers) are the primary option.

Nocturnal heart rate pauses may also be particularly arrhythmogenic in subsets of patients with the long QT syndrome, specifically LQTS2 and LQTS3; the latter have mutations on the sodium channel, voltage-gated, type V, α gene (SCN5A). The lethal arrhythmias in these syndrome subtypes occur almost exclusively at rest or during sleep. (See sections on SIDS and Brugada syndrome.) The effects of sleep and nocturnal apneas in the short QT syndrome have not been sufficiently investigated.

Reports vary of associations of apnea with nocturnal sinus pauses, heart block, or ventricular asystole or bradyarrhythmias. However, apnea treatment when indicated has been associated with reversal of sinus arrest and atrioventricular conduction block.

Atrial Fibrillation

Atrial fibrillation has serious consequences in terms of increased morbidity and mortality and afflicts 2.2 million people in the United States and 4.5 million in the European Union. Nocturnal peaks in onset of atrial tachyarrhythmias, paroxysmal atrial fibrillation, and a higher average nocturnal incidence of atrial fibrillation have been reported. Atrial fibrillation during sleep may be evident in a rise in heart rate (Figure 8).

It is likely that 10% to 25% of the arrhythmias are facilitated by vagal influences. Nocturnal atrial fibrillation is
provoked during periods of intense vagus nerve activity, as indicated by heart rate variability studies and by the presence of bradycardia in individuals with structurally normal hearts. These arrhythmias are termed “vagally mediated atrial fibrillation.” Enhanced adrenergic activity may interact in a complex manner with changes in vagal tone to affect atrial refractoriness and dispersion of repolarization and to alter intra-atrial conduction, thus increasing the propensity to develop this arrhythmia. The high level of vagus nerve tone maintained during slow-wave sleep has the capacity to exacerbate atrial fibrillation in patients whose atria are particularly prone to the arrhythmogenic influence of acetylcholine.

Risks of atrial fibrillation and its recurrence after cardioversion are more than doubled if breathing during sleep is disordered (Figure 9). Incidence of atrial fibrillation in patients with apnea is strongly predicted by obesity, by nocturnal oxygen desaturation in subjects <65 years old, and by heart failure in older subjects. Multiple mechanisms appear to be operative. Apnea provokes nocturnal hypoxemia, sympathetic nerve activity, and hemodynamic stress through surges in blood pressure that distend and remodel atrial chambers and can activate stretch receptors and alter diastolic function.

At present, there is no clear evidence for differentiating medical treatment for nighttime as compared with daytime atrial fibrillation. However, individuals with nocturnal onset of atrial fibrillation should be monitored for the presence of sleep-disordered breathing, which can be effectively treated by CPAP.

**SIDS**

SIDS is the leading cause of death in infants between 1 week and 1 year of age and typically occurs during sleep. The syndrome is diagnosed by exclusion criteria to include all causes that “remain unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of the clinical history.” The toll of SIDS is approximately 1 death per 2000 live births or 2500 total SIDS deaths in the United States annually and may be attributable to a variety of etiologies that challenge the developing cardiorespiratory system. Hypotension and bradycardia attend the fatal event in SIDS victims, suggesting a deficit in the normal reflex coordination of heart rate, arterial blood pressure, and respiration during sleep. This failure to respond to cardiorespiratory challenges during sleep has been attributed to a binding deficit in the arcuate nucleus of SIDS infants, as muscarinic cholinergic activity in this structure at the ventricular medullary surface is postulated to be involved in cardiorespiratory control. Absence of normal breathing pauses, diminished breathing variation, and reductions in respiration-induced heart rate variation characterize infants who later died of SIDS and may provide clues regarding derangements underlying the syndrome. Heart rates in these infants are generally higher and exhibit a reduced range, suggesting altered autonomic control.

Autonomic instability has also been documented in nonREM sleep in infants with aborted SIDS events.

Repolarization abnormalities have been observed among SIDS victims that typify infants and children with the long QT syndrome genotype linked to chromosome 3 (LQT3). Evidence from a 19-year, prospective, multicenter observational study of 34 442 infants determined that significant prolongation (35 ms or more) of the QT interval characterized the 24 (0.07%) infants who died of SIDS within the first year of life. These results suggest that some SIDS cases may be attributed to a genetic defect that produces a developmental abnormality in cardiac sympathetic innervation and alters repolarization to increase the risk of ventricular arrhythmia. Mutations in the sodium channel gene SCN5A are the most common causes of long QT syndrome and are responsible for the arrhythmias and reduced heart rates. The genetic locus of the defect and the length of the QT interval are independent predictors of risk, suggesting opportunities for assessing risk for SIDS through molecular screening as well as noninvasive ECG monitoring. T-wave alternans has been reported in infants who became SIDS victims or were successfully treated.

A number of straightforward opportunities for intervention are indicated, including placing infants in a supine (face-up) position for sleeping and avoidance of maternal smoking during gestation and passive smoking during the child’s...
infancy. Prospective studies are required to examine the potential of sodium channel blockade or cardiac pacing in treating infants diagnosed with the long QT3 syndrome. β-Blockade is the current treatment of choice and diminishes T-wave alternans magnitude.

The Brugada Syndrome and Sudden Unexplained Nocturnal Death

The striking phenomenon of sudden death during sleep caused by ventricular arrhythmia has been reported in Western adults diagnosed with the Brugada syndrome, which strikes men almost exclusively, and in young, apparently healthy Southeast Asian men with the sudden unexplained nocturnal death syndrome (SUNDS). The latter syndrome is named lai-tai (“sleep death”) in Laos, pokkuri (“sudden and unexpected death”) in Japan, and bangungut (“to rise and moan in sleep”) in the Philippines. These syndromes probably represent the same disorder, which is characterized by right precordial ST-segment elevation. The Brugada syndrome is considered responsible for 4% to 12% of all sudden cardiac deaths and for approximately 20% of deaths in patients with structurally normal hearts. A single sodium channel mutation in the SCN5A gene, QT-interval prolongation, and Brugada-like ECG characterizes 20% of Brugada patients; other mutations are suspected. Genetic defects in the sodium channel are also associated with progressive conduction system disease attended by bradycardia.

Autopsies of SUNDS cases have established that cardiovascular disease is absent, but, in some instances, that conduction pathways are developmentally abnormal. Vagal tone is lower in SUNDS survivors compared with healthy individuals, particularly at night. Currently, implantation of cardioverter-defibrillators appears to be the most effective approach in patients with Brugada syndrome or SUNDS.

Sleep-Disrupting Effects of Cardiac Medications

Several widely used cardiac medications have the potential to disrupt sleep, including antihypertensive agents and β-blockers, which reduce sudden death risk but cross the blood-brain barrier. The lipophilic β-blockers propranolol and metoprolol increase the total number of awakenings and total wakefulness compared with placebo and with the nonlipophilic atenolol and may provoke nightmares. Penetration of the blood-brain barrier occurs with prolonged therapy; when these distinctions may become less apparent. The mechanism of sleep disruption by β-blocking agents may be their well-known tendency to deplete endogenous melatonin, a key sleep-regulating hormone that modulates sympathetic nerve activity. Sleep disturbance has also been documented in conjunction with the widely prescribed antiarrhythmic agent amiodarone. Neurological side effects were attributed to amiodarone in 20% to 40% of patients.

Conclusions and Implications

The occurrence of serious ventricular and supraventricular arrhythmias during sleep in individuals with heart disease is an important problem in contemporary cardiology. The subtle nature of cardiovascular regulation during sleep belies the intensity of autonomic activity, which can challenge the diseased coronary circulation and myocardium.

Identification of risk and underlying pathophysiology on an individual patient basis remains a major challenge, requiring prospective trials that use streamlined risk-assessment tools suitable for use in the routine flow of clinical evaluation. Recent developments in ambulatory ECG-based technology for assessment of autonomic tone by heart rate turbulence and of cardiac electric instability by T-wave alternans may be useful. Given the important role of respiratory factors in sleep-related arrhythmogenesis, future studies should also incorporate simultaneous measurement of ventilation and oxygen saturation to advance our understanding of causal links. Arrhythmia vulnerability is often compounded by disordered nighttime breathing, but whether sleep apnea treatment is capable of reducing risk for atrial and ventricular fibrillation, myocardial infarction, and sudden death has not been established definitively and deserves intense investigation. Ultimately, multiparameter assessment could significantly improve diagnosis and therapy and reduce sleep-related arrhythmogenesis and cardiovascular death.

Sources of Funding

This study was supported by R21 HL085720 from the National Institutes of Health and by the Center for Integration of Medicine and Innovative Technology (CIMIT).

Disclosures

Dr Verrier is co-inventor of a patent for T-wave alternans measurement by the Modified Moving Average method, which was assigned to Beth Israel Deaconess Medical Center and licensed to GE Healthcare. He has received research equipment and honoraria from GE Healthcare and grant support from Medtronic, Inc.

References


Key Words: death sudden nervous system autonomic tachyarrhythmias heart failure sleep T-wave alternans repolarization diagnostic testing.
Impact of Sleep on Arrhythmogenesis
Richard L. Verrier and Mark E. Josephson

_Circ Arrhythm Electrophysiol_. 2009;2:450-459
doi: 10.1161/CIRCEP.109.867028

_Circulation: Arrhythmia and Electrophysiology_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circep.ahajournals.org/content/2/4/450

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Arrhythmia and Electrophysiology_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Arrhythmia and Electrophysiology_ is online at:
http://circep.ahajournals.org/subscriptions/